

## ALZHEIMER DISEASE PROGNOSIS USING MACHINE LEARNING

Kishore V\*<sup>1</sup>, Kavsik M\*<sup>2</sup>, Riyaz Ahamed S\*<sup>3</sup>, Anbarasa Pandian A\*<sup>4</sup>

\*<sup>1,2,3</sup>Student, Department Of Computer Science, Panimalar Institute Of Technology,  
Chennai, Tamil Nādu, India.

\*<sup>4</sup>Professor, Department Of Computer Science, Panimalar Institute Of Technology,  
Chennai, Tamil Nādu, India.

### ABSTRACT

Alzheimer's disease is a revolutionary mental disruption that inflicts ruin on mind and reasoning skills. Experts estimate that extra than 6 million americans, most people of whom are sixty five or older, can also have dementia due to Alzheimer's ailment. The fundamental signs and symptoms are memory loss and confusion. even though there may be no cure, capsules and control activities may additionally help to relieve signs and manifestation temporarily. It identifies the risk factors for AD and managing the condition. The proposed method entails developing a machine learning model capable of determining whether or not a person has AD. The best model is acclimated to forecast the outcome when different methods are compared.

**Keywords:** Alzheimer's Disease, Data Mining, Machine Learning, Prediction.

### I. INTRODUCTION

Alzheimer disease a sort of dementia, is a long-term illness that involves a loss of cognitive abilities and daily functioning. AD is a gradual disease that affects memory. At initially, someone suffering from Alzheimer's disease may feel disoriented and have trouble remembering things. The most continual cause of dementia in today's culture is AD. Alzheimer disease alters behaviour and destroys the brain, causing brain cells to die and memory and thinking to deteriorate. As people age, their possibilities of growing AD increase. Dementia is a growing and major public health concern; dementia is present in roughly 70% of all instances of Alzheimer's disease. Despite the fact that it is more frequent than some malignancies, it has received significantly less support for research and public health initiatives. This issue needs to be looked into right away in order to identify better and more effective Alzheimer's disease treatments[1]

### II. RELATED WORK


Simon J. Furney et al [2] proposed it is impossible for clinicians to determine which persons with MCI may develop dementia. The inability of doctors to count on betterment limits the utilization of MCI as a condition for therapy in avoidance studies, and as more patients appear with this disorder in the general population, the benefit of mci as a malady for cure in preventive trials is becoming increasingly common. This creates a significant clinical dilemma, as prior examination is a fundamental goal of health services. Some CSF bio chemical markers and practical tomography with PET, according to the research, could be used as markers to aid conversion prediction. Both methods, however, are expensive and not widely available. The goal of our research was to see if combining indicators that are more easily collected in ordinary clinical practise could help foresee the development of MCI to AD.

Liana G. Apostolova et al [3] proposed a significant progress has been achieved in the area of genetics, neuroimaging, clinical diagnosis, and staging of AD in recent years. Our capacity to see amyloid pathology in the brain is one of the top significant recent developments in AD that is still alive in human brain. The lately amended practice for diagnosing AD dementia include the use of biochemical markers as additional proof for hidden pathophysiology. The liable use of amyloid positron emission tomography has been established.

Our growing knowledge from the clinical perspective start, progression, neuroimaging, pathologic characteristics, genetics, and other risk factors for AD has an impact on clinical diagnosis and potential therapeutic strategies.

Subhea Yiming Ding et al [4] have created a dl pattern that foresee the final examination of AD, mci, or fluorine 18 FDG PET of the brain, and measure it to reciter's performance. A dl algorithm created for early prediction of Alzheimer disease utilising fluorine 18 fdg PET of the brain obtained eighty two percent specificity at hundred percent subtlety, an usual of 75.8 months before the final analysis.

Jyoti Islam et al [5] proposed Alzheimer is a serious neurological illness that affects the brain. It causes individuals forget their memories, mental functions, and the ability to carry on with daily tasks by destroying brain cells. AD is incurable, however early detection is helpful in reducing symptoms significantly. ML algorithms can substantially enhance the certainty of AD'S diagnosis. Medical image analysis using DL approaches has shown a lot of success in recent years. However, there has been comparably little research into using deep learning to detect and classify AD. Using Brain MRI data, this research proposes a unique dl model for AD detection and classification.



**Figure 1:** Diagram of generic Alzheimer Disease detection and classification framework

R.Anand et al [6] have studied Alzheimer disease is the primary cause of dementia in the world. The disease's genesis is multifactorial, and its pathophysiology is complicated. The total cases of Alzheimer disease is increasing at an exponential rate, highlighting the importance of establishing an effective therapy. AD also has a huge impact. The patient's family and community face an emotional and financial hardship. The disease has been researched extensively. The only medications now licenced for this condition are acetylcholinesterase inhibitors and memantine, which have been around for over a century for its administration. These medications provide symptomatic relief but do little to change the course of the disease process. A number of unique ways for altering the illness process have been devised. These therapies hold the greatest promise for treating Alzheimer's disease in the near future, since they are based on amyloid and tau proteins. Several potential medications have been entirely explored in presymptomatic research, but many have failed to yield effects in the clinical setting; thus, it is only sensible to learn from past failures.

Anna M. Barron et al [7] have proposed Alzheimer disease is a neurological illness that induces slow cognitive loss, speech and language impairments, and sensorimotor system failure, eventually leading to complete need on nursing care. The pathophysiology of Alzheimer disease, and many other age-related disorders has been linked to oxidative stress, which is generated by an inequality in the body's prooxidant and antioxidant processes. Although the hormones are well recognised for their reproductive functions, numerous studies have shown that they also have other functions, such as neuroprotection. Changes in these hormone levels that arise during reproductive senescence are thought to enhance the risk of AD by reducing defence against oxidative assaults.

Xiaoling Lu et al [8] showed a comprehensive feature on the number of senior individuals in China has risen drastically as the country's ageing population becomes more serious. At the meantime, the number of Alzheimer disease patients has risen. The major diagnosis procedure for AD now relies on professional manipulators analysing mind SNMR photographs to determine the condition. This could lead to a misdiagnosis. DL's Convolutional Neural Network gets exceptionally good performance when detecting MRI images of Alzheimer's patients and healthy controls (NC).

Mugdha Agarwal et al [9] have foundout that the Alzheimer disease , a neurological condition that progresses to death, AD has grow to be the most not unusual form of dementia these days. Long after cellular damage in the brain has begun, patients with AD begin to display clinical aspects, such as memory and cognition loss. There are various theories regarding the neurodegenerative process; however, due to a lack of in vivo models, it is impossible to replicate AD in humans. Furthermore, the presently available medications just treat the symptoms of the disease; there is no cure for it. The ineptide in breaking the intricacy of the disease aetiology and the inadequazy in delivering medications targeted for AD have been two main roadblocks in the search for the same.

Marcos Pais et al [10] have proposed Alzheimer disease , a progressive neurological condition. The pathophysiology of Alzheimer disease is transforming our understanding of the disease and paving the way for

novel drug development and therapy. The "amyloid cascade" and the "continuum of AD," These concepts are well established and discussed in this article. We want to examine the literature on AD, considering new definitions and problems that have evolved from latest studies, A new classification and recommendation are derived to advancements in prodrugs of AD. There are also updates on the status of key research studies, as well as discussion of future prospects.

I.A. Illan et al [11] have described that To develop early treatments, adaptable and sensitive tools monitoring and early diagnosis using noninvasive methods of Alzheimer disease are critical. In order to extract features, the feature space dimension reduction technique of image projection is mixed with eigen image based disintegration, and a support vector machine is used for allocation. By achieving meaningful classification performance, Supporting ultimate decision making through image analysis, a two-fold goal is realised. The accuracy in detecting mild Alzheimer's disease is 88.24 percent, with 88.64 percent specificity and 87.70 percent sensitivity. This approach can also be used to identify typical AD patterns in people with slight cognitive impairment.

Alvarez et al [12] have proposed for the patient's medical therapy, an exact and timely detection of AD is critical. Physicians frequently employ SPECT images to diagnosis. A computer assisted diagnosis tool feature space dimensional reduction methodology and a SVM method for enhancing AD interpretation clarity using SPECT images is presented. The main picture highlights were picked utilizing PCA pressure, which detects the deviation grid, and the extricated data has been used to prepare a SVM classifier that could apprehend new topics unaided.

Stefan Kloppel et al [13] have developed Structural MRI must be able to consistently discriminate Alzheimer disease from normal ageing in individual scans in order to be diagnostically valuable. Support vector machines have been applied to MRI for the detection of a range of illness conditions as a result of recent breakthroughs in statistical learning theory. The aim of this studies become to peer how nicely help vector machines assigned person diagnoses and whether or not statistics units compiled from various scanners and one of a kind centres might be used to categorise scans effectively. The purpose of this studies changed into to look how properly assist vector machines assigned person diagnoses and whether or not information units compiled from several scanners and specific centres can be used to categorise scans effectively. This shows that computer-assisted diagnostic picture processing has a significant function in clinical practise.

Qi Zhou et al [14] have suggested combining MRI data with the Mini mental status exam as input to a intricate area for AD. Thanks to a complex feature selection and ranking mechanism. With the use of FreeSurfer, 55 volumetric variables were calculated, which has been then modified for ICV, education etc. Support vector machines (SVM) classification results are based on two fold cross validation of fifty separate and randomised runs. According to the findings, MMSE scores have the greatest ability to distinguish between AD, aMCI, and naMCI. When paired with MMSE scores, the two most distinct volumetric factors showed a mean accuracy of ninty two percent for AD versus CN.

Peter A. Freeborough et al [15] have proposed the significance of magnetic resonance texture as a indicative marker and a range of headway in Alzheimer disease is examined. It has 2 groups: a training and a test group. In adding to it, 5 healthy people and five Alzheimer's sufferers were examined multiple times over years. On every scan there included the evaluation of a texture feature vector. This characteristic produced appreciably specific values for the control and advert companies within the take a look at set ( $p < 10^{-4}$ ), with simplest minor organization overlap; a category rate of 91% was acquired. The texture of an MR photograph may additionally be beneficial in the prognosis and monitoring of AD.

James A. Hendrix et al [16] have described the Alzheimer Disease Neuroimaging Initiative has strived to speed up medication evolvment by verifying image and blood fluid biomarkers in AD clinical tests. The ADNI programe in US is not one taking place in the globe. The Alzheimer Association recognised about it international struggle and established the World Alzheimer's Disease Network International (Worldwide ADNI). WW goals ADNI are to synchronize programme and findings around geographical regions and to make data collection and access easier for researches all over the globe by developing a pathway for global coaction.

Baiying Lei et al [17] have studied the early Alzheimer disease prognosis and analysis require rigorous identification and interpretation of informative features. To increase layer-specific differentiation and

consolidate computative information for efficient feature excerpt, we use a discriminative learning technique. Furthermore, two types of relational data are used to investigate the deep-seated affiliation between characteristics and training topics in terms of learning by similarity. Both discriminative learning and relational regularisation methods are combined in a single loss function.

Jun Zhang et al [18] have studied the use of techtonic MRI to analyse AD is a common and effective procedure. The 2 stagnant stages of erratic enrollment across connotation and brain tissue carving are critical success of computer proposed diagnostic ways using organised MRI data. During the training step assosiation analogy based on local linguistic features were used to find rain regions with considerable group dissimilarities to distinguish AD individuals from strong reins.

Roberto Hornero et al [19] have proposed the aim of this study was to test the aseline performance of magnetic photographs of patients with Alzheimers disease and the elderly. 2 apparitional and 2 designless limits were used to assess MEG readings from tewnty AD patients and twenty one controls. The accuracy of this model was 80.5 percent. We suggest that insubstantial and uncertain studies of unplanned MEG activity could be useful tools for detecting Alzheimer's disease.

Siqi Liu et al [20] have studied accurate Alzheimer disease diagnosis is critical for care of unwell, especially in the preceding stages. Despite the fact that numerous studies have lately used ml approaches for computer assisted symptomatic of AD, most existing investigations have found a bottleneck in diagnosis performance, owing to the hereditary constraints of the selected intelect ideals. To conquer the predicament and improve the identification of ad and its pre level, mild cognitive impairment, we evolved a dl architecture consisting of car-stacked codes and a softmax output layer.

Daoqiang Zhang et al [21] have proposed the analysis of AD and its underlying stage moderate cognitive impairment, many ML and pattern categorization algorithms have been used. Several paradigm regress algorithms have recently been applied to estimate stable analytic variables from mind scans, rather than reckoning categorical variables as in classifiers. In this research, we present a general methodology for jointly predicting several variables from multimodal data called multimodal multi-task (M3T) learning. The variables here comprise not just the analytic factors used in relapse but also the emphatic variables used in classifiers, with different tasks involving predictions of different variables.




Figure 2: Flowchart of the proposed M3T method

P. Padilla et al [22] have studied based totally on non negative matrix factorization and help vector machines with confidence constraints, this work provides a singular computer-aided diagnostic technique quick prophecy of AD. The CAD programme is used to analyse and categorise functional brain pictures. A SVM-primarily based classifier with selfbelief bounds for selection is used to classify the resulting NMF-converted units of facts,that have a reduced range of functions. With excellent sensitivity and specificity rates, the suggested approach achieves up to 91 percent classification accuracy.

Yong Fan et al [23] have studied that it relies on prior research that found that pattern categorization of MRI scans may accurately categorise people with moderate cognitive impairment, which is commonly a

introductory phase of AD. The contemporary studies combines MRI scans from 30 patients within the Baltimore Longitudinal take a look at of growing older to explore the speculation that combining structure and characteristic can improve category accuracy. Go away-one-out pass-validation yielded type quotes of up to hundred percentage accuracy. Where as careful estimations of generalisation performance in new scans generated an area underneath the acceptor operating function curve of zero.978 ,indicating accurate diagnostic accuracy.

Guy McKhann et al [24] have proposed Alzheimer disease is a retrogressive brain damage that strikes people in their middle or later years of life. Worsening of particular nerve cells, the arrival of neuritic plaques, and neurofibrillary tangles are pathogenic capabilities. Forebrain cholinergic systems, as well as noradrenergic systems that stimulate the telencephalon, may additionally display adjustments in transmitter-unique markers.

Ron Brookmeyera et al [25] describes that the goal is to became to estimate the everyday fear of ad and verify the brunt of treatment plans that delay the start of the disease. A debatable model was enforced in conjunction with global culture predictions from the UN and data from studies of AD risks. Through 2050, the prevalence will have quadrupled, with 1 in eighty five humans globally affected by the condition. We estimate that roughly 43% of common cases require high-level care, similar to that provided in a nursing home.

Richard Mayeux et al [26] have examined the medical data of 121 AD patients in a row. Patients with myoclonus or extrapyramidal symptoms exhibited a higher rate of intellectual fall and functional impairment in everyday activities. There were four groups of patients studied over the course of four years: myoclonic-severe Except for the group with myoclonus, no other demographic factors or age at onset were used to divide the subgroups. This research reveals that Alzheimer's disease is varied, and that specific clinical symptoms can help predict outcome.

ELAINE K . PERRY et al [27] proposed the cholinergic system's activities in autopsy brain tissue is studied in relation to ageing and AD. The events of choline acetyltransferase and acetylcholinesterase declined, butyrylcholinesterase got raised as the number of senile plaques grew in deranged and ranged old adults. These metabolic activity were studied further in relation to the ageing process in mentally healthy adults. The ones biochemical findings are steady with an extension of age-related nerve terminal changes to anomalies of cholinergic strategies in the disorder.

Farshad Falahati et al [28] have studies that in recent years, ml contrivances and multiple analysis of data approaches have been extensively used in AD research. Instinctive sorting methods offer tools for analysing this data and spotting disease-related trends in it.Current studies within the area of advert studies that used system studying and multivariate analysis are covered in this e-book. Research that used structural magnetic resonance imaging are the primary emphasis. Different research have used a diverse range of materials and procedures, resulting in a wide range of outcomes.

M. Tsolaki et al [29] have determined the pervasiveness and analytic correspond of extrapyramidal signs and symptoms in sufferer with possibly advert; to investigate the showing up of EPS in relation to the primary syndrome that prompted the patients to seek preventive help; as well as to look into the possibility of EPS serving as a predictor of the disease's clinical trajectory.

Sidong Liu et al [30] proposed the accurate AD diagnosis at various moments is critical for identifying patients at excessive risk of dementia and planning appropriate preventative or medications. We presented a new AD staging strategy in this study for the complete spectrum of AD, encompassing AD, moderate Cognitive Impairment with and with out advert conversions, and Cognitive regular corporations .Our approach encapsulated high structural multiple view traits produced from neuroimaging data in a reduced dimensional feature space, resulting in a more particular depiction than naive integrated features. When equated to the original sparse coding method, the LSCG algorithm demonstrated considerable improvements on all diagnosis groups, as validated by mri data from the ADNI baseline cohort.

#### PERFORMANCE METRICS

The Alzheimer detection sensitivity, specificity, accuracy, and mistake rate are measured using performance metrics.


$$Sensitivity = \frac{TP}{TP + TN} \times 100 \tag{1}$$

$$Specificity = \frac{TN}{FP + TN} \times 100 \tag{2}$$

$$Accuracy = \frac{TP + TN}{(TP + FP + TN + FN)} \times 100 \tag{3}$$

$$Error\ rate = 100 - Accuracy \tag{4}$$

Let TP is the True Positive, TN is the True Negative, FP is the False Positive, and FN is the False Negative[32].




**Figure 3:** The framework of extracting the ROICSE feature from the gray matter (GM) image for AD classification.

### III. ALZHEIMER PROBLEM AND CHALLENGES

The time from diagnosis to death varies as little as three or four years if the person is older than 80 when diagnosed, to as long as 10 or more years if the person is younger.

Alzheimer’s disease is currently ranked as the sixth leading cause of death in the United States, but recent estimates indicate that the disorder may rank third, just behind heart disease and cancer, as a cause of death for older people.[34]



**Figure 4:** Cerebral Hemisphere

### IV. ALZHEIMER SOLUTION

Current Alzheimer's medications can help for a time with memory symptoms and other cognitive changes. Cholinesterase inhibitors. These drugs work by boosting levels of cell-to-cell communication by preserving a chemical messenger that is depleted in the brain by Alzheimer's disease. Memantine (Namenda). This drug works in another brain cell communication network and slows the progression of symptoms with moderate to severe Alzheimer's disease.[33]

## V. CONCLUSION

Despite the boundless concession of the advantages of fair and correct disclosure, healthcare provider practices widely varies. A lot of studies which includes a recent scrutiny of Medicare records, state that 50 percent of patients diagnosed with AD were diagnosed by a doctor. custodian were one who mostly report disclosures, but over forty five percent did not report disclosures. Due to the intricacy of the diagnosis and discovery process, differences in patient-caregiver preferences, and differences in support networks and coping mechanisms between patients, the disclosure method needs to be handled in a manner that compliments the situation of every patient and their family. Improvements in such systems have the ability to enhance the care of single patients and reduce the pressure of illness on both caregivers and healthcare providers. [31]

## VI. REFERENCES

- [1] Jinwang Feng, Shao-Wu Zhang, Luonan Chen, and Alzheimer's Disease Neuroimaging Initiative, "Extracting ROI-Based Contourlet Subband Energy Feature from the sMRI Image for Alzheimer's Disease Classification" in IEEE 2020.
- [2] Simon J. Furney, Deborah Kronenberg, Andrew Simmons, Andreas Guntert, Richard J. Dobson, Petroula Proitsi, Lars Olof Wahlund, Iwona Kloszewska, Patrizia Mecocci, Hilkka Soininen, Magda Tsolaki, Bruno Vellas, Christian Spenger and Simon Lovestone, "Combinatorial Markers of Mild Cognitive Impairment Conversion to Alzheimer's Disease - Cytokines and MRI Measures Together Predict Disease Progression."
- [3] Liana G. Apostolova, MD, MS, FAAN, 2016, "Alzheimer Disease."
- [4] Yiming Ding, Jae Ho Sohn, Michael G. Kawczynski, Hari Trivedi, Roy Harnish, Nathaniel W. Jenkins, Dmytro Lituiev, Timothy P. Copeland, Mariam S. Aboian, Carina Mari Aparici, Spencer C. Behr, Robert R. Flavell, Shih-Ying Huang, Kelly A. Zalocusky, Lorenzo Nardo, Youngho Seo, Randall A. Hawkins, Miguel Hernandez Pampaloni, Dexter Hadley, Benjamin L. Franc, "A Deep Learning Model to Predict a Diagnosis of Alzheimer Disease by Using 18F-FDG PET of the Brain."
- [5] Jyoti Islam and Yanqing Zhang, 2017, "A Novel Deep Learning Based Multi-class Classification Method for Alzheimer's Disease Detection Using Brain MRI Data."
- [6] R. Anand, Kiran Dip Gill, Abbas Ali Mahdi, "Therapeutics of Alzheimer's disease: Past, present and future."
- [7] ANNA M. BARRON, STEPHANIE J. FULLER, GIUSEPPE VERDILE, and RALPH N. MARTINS "Reproductive Hormones Modulate Oxidative Stress in Alzheimer's Disease", 2006
- [8] Xiaoling Lu, Haifeng Wu and Yu Zeng, "Classification of Alzheimer's disease in MobileNet."
- [9] Mugdha Agarwal, Mohammad Rizwan Alam, Mohd Kabir Haider, Md. Zubair Malik and Dae-Kwang Kim, "Alzheimer's Disease: An Overview of Major Hypotheses and Therapeutic Options in Nanotechnology."
- [10] Marcos Pais, Luana Martinez, Octavio Ribeiro, Julia Loureiro, Romel Fernandez, Leandro Valiengo, Paulo Canineu, Florindo Stella, Leda Talib, Marcia Radanovic, Orestes V. Forlenza, "Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges", 2020
- [11] I.A. Illan, J.M. Gorriz, J. Ramirez, D. Salas-Gonzalez, M.M. Lopez, F. Segovia, R. Chaves, M. Gomez-Rio, C.G. Puntonet, "18F-FDG PET imaging analysis for computer aided Alzheimer's diagnosis", 2010.
- [12] I. Alvarez, J.M. Gorriz, J. Ramirez, D. Salas-Gonzalez, M. Lopez, C.G. Puntonet and F. Segovia, "Alzheimer's diagnosis using eigenbrains and support vector machines"
- [13] Stefan Kloppel, Cynthia M. Stonnington, Carlton Chu, Bogdan Draganski, Rachael I. Scahill, Jonathan D. Rohrer, Nick C. Fox, Clifford R. Jack Jr, John Ashburner and Richard S. J. Frackowiak "Automatic classification of MR scans in Alzheimer's disease", 2008.
- [14] Qi Zhou, Mohammed Goryawala, Mercedes Cabrerizo, Jin Wang, Warren Barker, David Loewenstein, Ranjan Duara and Malek Adjouadi. "An Optimal Decisional Space for the Classification of Alzheimer's Disease and Mild Cognitive Impairment", 2014.

- [15] Peter A. Freeborough and Nick C. Fox, "MR Image Texture Analysis Applied to the Diagnosis and Tracking of Alzheimer's Disease", 1998
- [16] "The Worldwide Alzheimer's Disease Neuroimaging Initiative", 2015
- [17] James A. Hendrix, Brad Finger , Michael W. Weiner, Giovanni B. Frisoni , Takeshi Iwatsubo , Christopher C. Rowe, Seong Yoon Kim , Salvador M. Guinjoan , Gustavo Sevlever , Maria C. Carrillo, "Relational-Regularized Discriminative Sparse Learning for Alzheimer's Disease Diagnosis", Baiying Lei, Member, IEEE, Peng Yang, Tianfu Wang, Siping Chen, and Dong Ni, Member, IEEE.
- [18] Jun Zhang, Yue Gao, Senior Member, IEEE, Yaozong Gao, Brent C. Munsell, Dinggang Shen, Senior Member, "Detecting Anatomical Landmarks for Fast Alzheimer's Disease Diagnosis", IEEE.
- [19] Roberto Hornero, Member, IEEE, Javier Escudero, Student Member, IEEE, Alberto Fernandez, Jesus Poza , Student Member, IEEE, and Carlos Gomez , Student Member, IEEE "Spectral and Nonlinear Analyses of MEG Background Activity in Patients With Alzheimer's Disease".
- [20] Siqi Liu, Sidong Liu, Student Member, IEEE, Weidong Cai, Member, IEEE, Sonia Pujol , Ron Kikinis , Dagan Feng, Fellow, IEEE. "EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE WITH DEEP LEARNING",2014.
- [21] Daoqiang Zhang, Dinggang Shen, and The Alzheimer's Disease Neuroimaging Initiative , "Multi-modal multi-task learning for joint prediction of multiple regression and classification variables in Alzheimer's disease".
- [22] P. Padilla, M. Lopez, J. M. Gorriz, J. Ramirez, D. Salas-Gonzalez, I. Alvarez, and The Alzheimer's Disease Neuroimaging Initiative, "NMF-SVM Based CAD Tool Applied to Functional Brain Images for the Diagnosis of Alzheimer's Disease".
- [23] Yong Fan, Susan M. Resnick, Xiaoying Wu and Christos Davatzikos, "Structural and functional biomarkers of prodromal Alzheimer's disease: A high-dimensional pattern classification study", 2008
- [24] Guy McKhann, David Drachman, Marshall Folstein, et al, "Clinical diagnosis of Alzheimer's disease: Report of the NINCDS- ADRDA Work Group under the auspices of Department of Health ADRDA Work Group and Human Services Task Force on Alzheimer's Disease ", 1984.
- [25] Ron Brookmeyer, Elizabeth Johnson, Kathryn Ziegler-Graham , H. Michael Arrighi, "Forecasting the global burden of Alzheimer's disease", 2007.
- [26] Richard Mayeux, MD, Yaakov Stern, PhD, and Susan Spanton , "Heterogeneity in dementia of the Alzheimer type: Evidence of subgroups".
- [27] ELAINE K. PERRY , "THE CHOLINERGIC SYSTEM IN OLD AGE AND ALZHEIMER'S DISEASE", 1980
- [28] Farshad Falahati, Eric Westman, and Andrew Simmons, "Multivariate Data Analysis and Machine Learning in Alzheimer's Disease with a Focus on Structural Magnetic Resonance Imaging", 2014.
- [29] M. Tsolaki, MD, PhD K. Kokarida, MD V. Iakovidou, MD E. Stilopoulos, MD J. Meimaris, MD A. Kazis, MD, PhD, "Extrapyramidal symptoms and signs in Alzheimer's disease: Prevalence and correlation with the first symptom", 2001
- [30] Sidong Liu, Student Member, IEEE, Weidong Cai, Member, IEEE, Yang Song, Student Member, IEEE, Sonia Pujol, Ron Kikinis, Lingfeng Wen, Member, IEEE, David Dagan Feng, Fellow, IEEE , "Localized Sparse Code Gradient in Alzheimer's Disease Staging", 2013
- [31] Alzheimer's Association , "2015 Alzheimer's disease facts and figures".
- [32] Pandian, A. Anbarasa, and R. Balasubramanian. "Fusion of contourlet transform and zernike moments using content based image retrieval for MRI brain tumor images." Indian Journal of Science and Technology 9.29 (2016): 29-29.
- [33] [https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/diagnosis-treatment/drc-20350453#:~:text=Memantine%20\(Namenda\).&text=In%20June%202021%2C%20the%20Food,amyloid%20plaques%20in%20the%20brain.](https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/diagnosis-treatment/drc-20350453#:~:text=Memantine%20(Namenda).&text=In%20June%202021%2C%20the%20Food,amyloid%20plaques%20in%20the%20brain.)
- [34] <https://www.nia.nih.gov/health/what-alzheimers-disease>